

## Poolbeg Pharma plc

### Annual Report, AGM Notice & Circular

27 May 2025 - [Poolbeg Pharma](#) (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, confirms that the Company's Annual Report and Accounts for the period ended 31 December 2024 and the notice of Annual General Meeting ("AGM") will be posted to shareholders today.

The 2024 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy are available to download from the Company's website: [www.poolbegpharma.com](http://www.poolbegpharma.com)

The Annual General Meeting will be held at the offices of DAC Beachcroft LLP, 25 Walbrook, London EC4N 8AF, United Kingdom at 12pm on 23 June 2025.

Further to the Company's announcement on [20 May 2025](#), a Circular containing details of the Fundraising and convening a general meeting, along with an accompanying form of proxy, will also be posted to Shareholders today. The Circular is available on the Company's website at [www.poolbegpharma.com](http://www.poolbegpharma.com).

#### Enquiries

**Poolbeg Pharma Plc**  
Jeremy Skillington, CEO  
Ian O'Connell, CFO

+44 (0) 207 183 1499  
[ir@poolbegpharma.com](mailto:ir@poolbegpharma.com)

**Cavendish Capital Markets Ltd (NOMAD & Joint Broker)**  
Geoff Nash, Trisya Jamaludin (Corporate Finance)  
Nigel Birks (Life Science Specialist Sales)  
Harriet Ward (ECM)

+44 (0) 207 220 0500

**Shore Capital Stockbrokers Ltd (Joint Broker)**  
David Coaten, Harry Davies-Ball (Corporate Advisory)  
Malachy McEntyre, Isobel Jones (Corporate Broking)

+44 (0) 207 408 4090

**J&E Davy (Joint Broker)**  
Anthony Farrell, Niall Gilchrist

+353 (0) 1 679 6363

**Optimum Strategic Communications**  
Nick Bastin, Vici Rabbetts, Elena Bates

+44 (0) 208 078 4357  
[poolbeg@optimumcomms.com](mailto:poolbeg@optimumcomms.com)

#### About Poolbeg Pharma plc

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs. The Company's clinical programmes target large addressable markets including, cancer immunotherapy-induced Cytokine Release Syndrome ("CRS") and metabolic conditions such as obesity with the development of an oral encapsulated glucagon-like peptide GLP-1R agonist.

For more information, please go to [www.poolbegpharma.com](http://www.poolbegpharma.com) or follow us on [Twitter](#) and [LinkedIn](#) @PoolbegPharma.

#### Forward-Looking Statements

This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAQXLFLEELXBBB